We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Psychedelics – News and Features

Article

“Special K” could offer new hope for treatment-resistant depression

Over the past several decades, the pharmaceutical industry has been abandoning the research and development of treatments for psychiatric disorders, despite the ever-growing need for novel, more efficacious, and better targeted therapeutics.
News

Psychedelic therapy re-emerging for anxiety, PTSD and addiction

Renewed medical interest in the use of psychedelic drugs for anxiety, posttraumatic stress disorder (PTSD) and addiction has resulted in small research studies that show some success with the controlled use of these drugs, according to an analysis published in CMAJ (Canadian Medical Association Journal).
News

Allergan to Acquire Naurex

The acquisition will strengthen Allergan's long-term growth profile with the addition of Naurex's lead development product rapastinel (GLYX-13), a once-weekly intravenous Phase 3-ready molecule that has demonstrated rapid, robust and sustained efficacy in multiple Phase 2 clinical studies in depression.
News

This Week on NeuroScientistNews: 06 July – 10 July

LSD-induced synesthesia; stress resiliency and susceptibility; bacterial biofilms and MS, and more.
Article

Trippy research: Chemically-induced synesthesia

In April 1943, scientist Albert Hoffman ingested 250 micrograms of a substance he had synthesized five years prior. Less than an hour later, he “perceived an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors.
News

The ecstasy and the agony: compression studies of MDMA

MDMA (3,4-methyenedioxymethamphetamine), a Class A substance that is usually found in a tableted form, is a psychoactive drug which is structurally similar to methylamphetamine and acts as a central nervous system stimulant, producing mood enhancement, increased energy and other empathetic effects.
News

Research finds psychedelic drug prevents asthma development in mice

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the Louisiana State University (LSU) Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.
News

LLNL, UC Davis Partner to Personalize Cancer Medications

With a $7.8 million, five-year grant from the NIH researchers are utilizing accelerator mass spectrometry for cancer research.
News

Rapid agent restores pleasure-seeking ahead of other antidepressant action

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of — and ahead of — its other antidepressant effects, in a National Institutes of Health trial.
News

The bit of your brain that signals how bad things could be

An evolutionarily ancient and tiny part of the brain tracks expectations about nasty events, finds new research The study, published in Proceedings of the National Academy of Sciences, demonstrates for the first time that the human habenula, half the size of a pea, tracks predictions about negative events, like painful electric shocks, suggesting a role in learning from bad experiences.
Advertisement